Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rivoltini

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Folia Biologica|January 1, 1996
Cytokine-based gene therapy of human tumors. An overviewG Parmiani, F Arienti, J Sulé-Suso, et al.
The Cancer Journal From Scientific American|January 1, 1997
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan AJ N Cormier, M L Salgaller, T Prevette, et al.
The Journal of Experimental Medicine|August 1, 1996
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)D J Loftus, C Castelli, T M Clay, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1995
Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytesP F Robbins, M el-Gamil, Y F Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1995
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1L Rivoltini, Y Kawakami, K Sakaguchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1996
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytesA Mazzocchi, W J Storkus, C Traversari, et al.
Cancer Research|October 15, 1994
Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitopeD J Cole, D P Weil, P Shamamian, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocolsM A Player, K C Barracchini, T B Simonis, et al.
Cancer Research|July 15, 1995
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytesL Rivoltini, K C Barracchini, V Viggiano, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Folia Biologica|January 1, 1996
Cytokine-based gene therapy of human tumors. An overviewG Parmiani, F Arienti, J Sulé-Suso, et al.
The Cancer Journal From Scientific American|January 1, 1997
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan AJ N Cormier, M L Salgaller, T Prevette, et al.
The Journal of Experimental Medicine|August 1, 1996
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)D J Loftus, C Castelli, T M Clay, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1995
Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytesP F Robbins, M el-Gamil, Y F Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1995
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1L Rivoltini, Y Kawakami, K Sakaguchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1996
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytesA Mazzocchi, W J Storkus, C Traversari, et al.
Cancer Research|October 15, 1994
Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitopeD J Cole, D P Weil, P Shamamian, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocolsM A Player, K C Barracchini, T B Simonis, et al.
Cancer Research|July 15, 1995
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytesL Rivoltini, K C Barracchini, V Viggiano, et al.
Pageof 9